ClinicaliQ Trial Snapshot
- Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection — Recruiting • Phase I • Oncology • NCT05413850.
- Sponsor: Blue Earth Therapeutics Ltd.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Eligibility Snapshot
- : 1. Male subjects, 18 years of age or older with histologically confirmed adenocarcinoma of the prostate. 2. Serum testosterone levels
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.